Affordable Access

deepdyve-link
Publisher Website

Antenatal corticosteroid therapy is associated with a lower risk of cystic periventricular leukomalacia.

Authors
  • Hershkovich Shporen, Calanit1
  • Reichman, Brian2, 3
  • Zaslavsky-Paltiel, Inna2
  • Lerner-Geva, Liat2, 3
  • Flidel-Rimon, Orna1, 4
  • 1 Department of Neonatology, Kaplan Medical Center, Rehovot, Israel. , (Israel)
  • 2 Women and Children's Health Research Unit, Gertner Institute for Epidemiology and Health Policy Research, Tel-Hashomer, Israel. , (Israel)
  • 3 Sackler School of Medicine, Tel Aviv University, Tel Aviv-Yafo, Israel. , (Israel)
  • 4 The Hebrew University of Jerusalem, Jerusalem, Israel. , (Israel)
Type
Published Article
Journal
Acta Paediatrica
Publisher
Wiley (Blackwell Publishing)
Publication Date
Jun 01, 2021
Volume
110
Issue
6
Pages
1795–1802
Identifiers
DOI: 10.1111/apa.15772
PMID: 33484164
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

To evaluate the association of antenatal corticosteroids (ACS) therapy on the risk for cystic periventricular leukomalacia (c-PVL) in very low birth weight (VLBW), very preterm infants, whilst accounting for the occurrence of major neonatal morbidities; sepsis, necrotising enterocolitis, intraventricular haemorrhage and bronchopulmonary dysplasia. Population-based observational cohort study applying data collected by the Israel national VLBW infant database from 1995-2016. Cystic PVL was diagnosed in 692 (6.8%) of the 10,170 study infants. Among 7522 infants exposed to ACS, the rate of c-PVL was 5.4%, compared to 10.7% among those not exposed (p < 0.0001). ACS was associated with significantly lower odds for c-PVL (Odds Ratio [OR] 0.69, 95% confidence interval [CI] 0.57-0.84). In subgroup analyses, excluding infants with one or more morbidities the rates of c-PVL ranged from 2.7% to 5.4% among infants exposed to ACS compared to 5.6% to 10.7% in those not exposed (all p < 0.0001). ACS was associated with significantly lower OR's for c-PVL in all subgroups, ranging from 0.52 (95% CI 0.40-0.66) to 0.62 (95% CI 0.50-0.77). Infants exposed to ACS had a significantly lower risk of c-PVL. Subgroup analyses excluding infants with major neonatal comorbidities showed a consistent reduction of 40%-50% in the risk for c-PVL following ACS therapy. ©2021 Foundation Acta Paediatrica. Published by John Wiley & Sons Ltd.

Report this publication

Statistics

Seen <100 times